[SCHEDULE 13G/A] Skye Bioscience, Inc. SEC Filing
Schonfeld Strategic Advisors LLC filed an amendment to a Schedule 13G reporting ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock, representing 3.60% of the class. The filing states those shares are held for the ordinary course of business and not for the purpose of influencing control. Schonfeld reports sole voting and dispositive power over the reported shares and notes that some shares are held in separately managed accounts for clients who retain the right to dividends or sale proceeds.
Schonfeld Strategic Advisors LLC ha presentato un emendamento al Schedule 13G dichiarando la propriet脿 di 1,115,939 azioni ordinarie di Skye Bioscience, Inc., pari al 3,60% della classe. La documentazione precisa che tali azioni sono detenute nell'ordinario svolgimento dell'attivit脿 e non con l'intento di influenzare il controllo. Schonfeld dichiara di avere il pieno diritto di voto e di disposizione sulle azioni segnalate e osserva che alcune azioni sono detenute in conti gestiti separatamente per clienti che mantengono il diritto ai dividendi o al ricavato della vendita.
Schonfeld Strategic Advisors LLC present贸 una enmienda al Schedule 13G informando la propiedad de 1,115,939 acciones ordinarias de Skye Bioscience, Inc., que representan el 3,60% de la clase. La presentaci贸n indica que esas acciones se mantienen en el curso ordinario del negocio y no con el prop贸sito de influir en el control. Schonfeld informa tener el poder exclusivo de voto y de disposici贸n sobre las acciones reportadas y se帽ala que algunas acciones se mantienen en cuentas gestionadas por separado para clientes que conservan el derecho a los dividendos o al producto de la venta.
Schonfeld Strategic Advisors LLC電� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頃橃棳 Skye Bioscience, Inc.鞚� 氤错喌欤� 1,115,939欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 霌标笁鞚� 3.60%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕霌れ澊 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. Schonfeld電� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚茧秬 欤检嫕鞚� 氚半嫻旮� 霕愲姅 毵り皝雽�旮堨棎 雽�頃� 甓岆Μ毳� 氤挫湢頃� 瓿犼皾鞚� 鞙勴暣 氤勲弰 甏�毽� 瓿勳鞐� 氤搓磤霅橃柎 鞛堨潓鞚� 鞏戈笁頃橁碃 鞛堨姷雼堧嫟.
Schonfeld Strategic Advisors LLC a d茅pos茅 un amendement au Schedule 13G d茅clarant la d茅tention de 1,115,939 actions ordinaires de Skye Bioscience, Inc., repr茅sentant 3,60% de la cat茅gorie. le d茅p么t pr茅cise que ces actions sont d茅tenues dans le cours normal des affaires et non dans le but d'influencer le contr么le. Schonfeld indique d茅tenir le pouvoir de vote et le pouvoir de disposition exclusifs sur les actions d茅clar茅es et signale que certaines actions sont d茅tenues dans des comptes g茅r茅s s茅par茅ment pour des clients qui conservent le droit aux dividendes ou au produit de la vente.
Schonfeld Strategic Advisors LLC hat eine 脛nderung zu einem Schedule 13G eingereicht und meldet den Besitz von 1,115,939 Aktien von Skye Bioscience, Inc. Stammaktien, was 3,60% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien im normalen Gesch盲ftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Schonfeld berichtet, 眉ber die gemeldeten Aktien alleinige Stimm- und Verf眉gungsgewalt zu haben und weist darauf hin, dass einige Aktien in separat verwalteten Konten f眉r Kunden gehalten werden, die das Recht auf Dividenden oder Verkaufserl枚se behalten.
- None.
- None.
Insights
TL;DR: Routine Schedule 13G/A disclosing a sub-5% passive stake, indicating monitoring rather than activist intent.
The filing reports a 3.60% stake (1,115,939 shares) held with sole voting and dispositive power by Schonfeld Strategic Advisors LLC. Under applicable rules, this level of ownership is below the 5% threshold that typically triggers more intensive disclosure and potential activist signaling. The certification language expressly states the position is held in the ordinary course of business and not to influence control, which supports a non-activist posture. For investors, this is a transparency disclosure rather than a material governance event.
TL;DR: Disclosure aligns with standard governance practice for institutional holders below 5%.
The amendment clarifies beneficial ownership and confirms sole voting and dispositive authority for the reported shares. Schonfeld also notes ownership may include securities held in Schonfeld-managed SMAs where clients are record owners and retain economic rights. No group affiliation or control assertions are made. This filing does not indicate a change in control intent and is consistent with routine reporting obligations under the Exchange Act.
Schonfeld Strategic Advisors LLC ha presentato un emendamento al Schedule 13G dichiarando la propriet脿 di 1,115,939 azioni ordinarie di Skye Bioscience, Inc., pari al 3,60% della classe. La documentazione precisa che tali azioni sono detenute nell'ordinario svolgimento dell'attivit脿 e non con l'intento di influenzare il controllo. Schonfeld dichiara di avere il pieno diritto di voto e di disposizione sulle azioni segnalate e osserva che alcune azioni sono detenute in conti gestiti separatamente per clienti che mantengono il diritto ai dividendi o al ricavato della vendita.
Schonfeld Strategic Advisors LLC present贸 una enmienda al Schedule 13G informando la propiedad de 1,115,939 acciones ordinarias de Skye Bioscience, Inc., que representan el 3,60% de la clase. La presentaci贸n indica que esas acciones se mantienen en el curso ordinario del negocio y no con el prop贸sito de influir en el control. Schonfeld informa tener el poder exclusivo de voto y de disposici贸n sobre las acciones reportadas y se帽ala que algunas acciones se mantienen en cuentas gestionadas por separado para clientes que conservan el derecho a los dividendos o al producto de la venta.
Schonfeld Strategic Advisors LLC電� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頃橃棳 Skye Bioscience, Inc.鞚� 氤错喌欤� 1,115,939欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 霌标笁鞚� 3.60%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕霌れ澊 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. Schonfeld電� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚茧秬 欤检嫕鞚� 氚半嫻旮� 霕愲姅 毵り皝雽�旮堨棎 雽�頃� 甓岆Μ毳� 氤挫湢頃� 瓿犼皾鞚� 鞙勴暣 氤勲弰 甏�毽� 瓿勳鞐� 氤搓磤霅橃柎 鞛堨潓鞚� 鞏戈笁頃橁碃 鞛堨姷雼堧嫟.
Schonfeld Strategic Advisors LLC a d茅pos茅 un amendement au Schedule 13G d茅clarant la d茅tention de 1,115,939 actions ordinaires de Skye Bioscience, Inc., repr茅sentant 3,60% de la cat茅gorie. le d茅p么t pr茅cise que ces actions sont d茅tenues dans le cours normal des affaires et non dans le but d'influencer le contr么le. Schonfeld indique d茅tenir le pouvoir de vote et le pouvoir de disposition exclusifs sur les actions d茅clar茅es et signale que certaines actions sont d茅tenues dans des comptes g茅r茅s s茅par茅ment pour des clients qui conservent le droit aux dividendes ou au produit de la vente.
Schonfeld Strategic Advisors LLC hat eine 脛nderung zu einem Schedule 13G eingereicht und meldet den Besitz von 1,115,939 Aktien von Skye Bioscience, Inc. Stammaktien, was 3,60% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien im normalen Gesch盲ftsverlauf gehalten werden und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Schonfeld berichtet, 眉ber die gemeldeten Aktien alleinige Stimm- und Verf眉gungsgewalt zu haben und weist darauf hin, dass einige Aktien in separat verwalteten Konten f眉r Kunden gehalten werden, die das Recht auf Dividenden oder Verkaufserl枚se behalten.
